Overview

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development Ltd
Prostrakan Pharmaceuticals
Treatments:
Granisetron